It showed a trend towards a lower risk of clinical adverse events at 30 days in the CA125-guided group.[ 57 ] CA125 also has a potential role in personalising diuretic therapy after hospitalisation for AHF.
← all excerpts
Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions.
1
—
—